CN101912361B - 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 - Google Patents
一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 Download PDFInfo
- Publication number
- CN101912361B CN101912361B CN2010102391745A CN201010239174A CN101912361B CN 101912361 B CN101912361 B CN 101912361B CN 2010102391745 A CN2010102391745 A CN 2010102391745A CN 201010239174 A CN201010239174 A CN 201010239174A CN 101912361 B CN101912361 B CN 101912361B
- Authority
- CN
- China
- Prior art keywords
- injection
- solution
- cefotiam hydrochloride
- hours
- sodium carbonate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- BWRRTAXZCKVRON-DGPOFWGLSA-N cefotiam dihydrochloride Chemical compound Cl.Cl.CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 BWRRTAXZCKVRON-DGPOFWGLSA-N 0.000 title claims abstract description 43
- 229960004700 cefotiam hydrochloride Drugs 0.000 title claims abstract description 43
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 title claims abstract description 41
- 238000002347 injection Methods 0.000 title claims abstract description 33
- 239000007924 injection Substances 0.000 title claims abstract description 33
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 239000000725 suspension Substances 0.000 title claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 36
- 206010043784 Thyroiditis subacute Diseases 0.000 claims abstract description 8
- 201000007497 subacute thyroiditis Diseases 0.000 claims abstract description 8
- 239000000243 solution Substances 0.000 claims description 29
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 18
- 239000000839 emulsion Substances 0.000 claims description 18
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 claims description 18
- 238000011282 treatment Methods 0.000 claims description 18
- 238000005516 engineering process Methods 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000008215 water for injection Substances 0.000 claims description 15
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003814 drug Substances 0.000 claims description 11
- 238000004108 freeze drying Methods 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 235000012000 cholesterol Nutrition 0.000 claims description 9
- 235000010265 sodium sulphite Nutrition 0.000 claims description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 8
- JGSARLDLIJGVTE-UHFFFAOYSA-N 3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-UHFFFAOYSA-N 0.000 claims description 8
- 229920003081 Povidone K 30 Polymers 0.000 claims description 8
- 239000000084 colloidal system Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 206010013786 Dry skin Diseases 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 5
- 108010010803 Gelatin Proteins 0.000 claims description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 239000008273 gelatin Substances 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 235000011852 gelatine desserts Nutrition 0.000 claims description 5
- 239000008101 lactose Substances 0.000 claims description 5
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 4
- 229930195725 Mannitol Natural products 0.000 claims description 4
- 229930003427 Vitamin E Natural products 0.000 claims description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 4
- 239000000594 mannitol Substances 0.000 claims description 4
- 235000010355 mannitol Nutrition 0.000 claims description 4
- 229940093429 polyethylene glycol 6000 Drugs 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 235000019165 vitamin E Nutrition 0.000 claims description 4
- 229940046009 vitamin E Drugs 0.000 claims description 4
- 239000011709 vitamin E Substances 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 abstract description 10
- 239000003381 stabilizer Substances 0.000 abstract description 10
- 239000003995 emulsifying agent Substances 0.000 abstract description 8
- 239000000654 additive Substances 0.000 abstract description 6
- 230000000996 additive effect Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
- 210000001685 thyroid gland Anatomy 0.000 description 12
- 210000003743 erythrocyte Anatomy 0.000 description 11
- 238000004062 sedimentation Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 229960001242 cefotiam Drugs 0.000 description 8
- 206010018498 Goitre Diseases 0.000 description 6
- 206010043757 Thyroid pain Diseases 0.000 description 6
- 238000006065 biodegradation reaction Methods 0.000 description 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- -1 cefotiam hydrochlorides Chemical class 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000008103 glucose Substances 0.000 description 5
- 201000003872 goiter Diseases 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000036760 body temperature Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 4
- 229960004618 prednisone Drugs 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- QYQDKDWGWDOFFU-IUODEOHRSA-N Cefotiam Chemical compound CN(C)CCN1N=NN=C1SCC1=C(C(O)=O)N2C(=O)[C@@H](NC(=O)CC=3N=C(N)SC=3)[C@H]2SC1 QYQDKDWGWDOFFU-IUODEOHRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 description 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229960004048 pantoprazole sodium Drugs 0.000 description 2
- YNWDKZIIWCEDEE-UHFFFAOYSA-N pantoprazole sodium Chemical compound [Na+].COC1=CC=NC(CS(=O)C=2[N-]C3=CC=C(OC(F)F)C=C3N=2)=C1OC YNWDKZIIWCEDEE-UHFFFAOYSA-N 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000004626 polylactic acid Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 206010043778 thyroiditis Diseases 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010004142 Bartholinitis Diseases 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000588923 Citrobacter Species 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 206010014568 Empyema Diseases 0.000 description 1
- 208000004145 Endometritis Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 208000015023 Graves' disease Diseases 0.000 description 1
- 208000001204 Hashimoto Disease Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000004575 Infectious Arthritis Diseases 0.000 description 1
- 208000032376 Lung infection Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000588771 Morganella <proteobacterium> Species 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- 206010033847 Parametritis Diseases 0.000 description 1
- 206010034686 Peritonsillar abscess Diseases 0.000 description 1
- 206010049592 Peritonsillitis Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000588777 Providencia rettgeri Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- 244000173166 Pyrus ussuriensis Species 0.000 description 1
- 235000011572 Pyrus ussuriensis Nutrition 0.000 description 1
- 206010049677 Salpingo-oophoritis Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 206010067868 Skin mass Diseases 0.000 description 1
- 206010042343 Subcutaneous abscess Diseases 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 241000473945 Theria <moth genus> Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000011923 Thyrotropin Human genes 0.000 description 1
- 108010061174 Thyrotropin Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 201000009267 bronchiectasis Diseases 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000003167 cholangitis Diseases 0.000 description 1
- 201000001352 cholecystitis Diseases 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 208000035824 paresthesia Diseases 0.000 description 1
- 230000007119 pathological manifestation Effects 0.000 description 1
- 206010034674 peritonitis Diseases 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001993 poloxamer 188 Polymers 0.000 description 1
- 229940044519 poloxamer 188 Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 201000006489 suppurative thyroiditis Diseases 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 201000005060 thrombophlebitis Diseases 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 229960000874 thyrotropin Drugs 0.000 description 1
- 230000001748 thyrotropin Effects 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102391745A CN101912361B (zh) | 2010-07-29 | 2010-07-29 | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2010102391745A CN101912361B (zh) | 2010-07-29 | 2010-07-29 | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101912361A CN101912361A (zh) | 2010-12-15 |
CN101912361B true CN101912361B (zh) | 2012-03-07 |
Family
ID=43320119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2010102391745A Expired - Fee Related CN101912361B (zh) | 2010-07-29 | 2010-07-29 | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101912361B (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102204915B (zh) * | 2011-04-01 | 2012-11-21 | 罗诚 | 一种含盐酸头孢替安化合物的药物组合物及其制备方法 |
CN103159787A (zh) * | 2011-12-13 | 2013-06-19 | 辽宁海思科制药有限公司 | 一种高纯度无菌盐酸头孢替安的制备方法以及包含该盐酸头孢替安的药物组合物 |
CN102716096B (zh) * | 2012-07-03 | 2013-07-03 | 哈药集团制药总厂 | 一种含有头孢替安的药物组合物 |
CN105055424A (zh) * | 2015-09-17 | 2015-11-18 | 青岛华之草医药科技有限公司 | 一种抗感染药物盐酸头孢替安组合物 |
CN109453178A (zh) * | 2018-12-06 | 2019-03-12 | 辽宁海思科制药有限公司 | 一种盐酸头孢替安组合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101584665A (zh) * | 2009-07-17 | 2009-11-25 | 山东罗欣药业股份有限公司 | 一种盐酸头孢替安药物组合物无菌粉针剂及其制备方法 |
CN101785756A (zh) * | 2010-01-26 | 2010-07-28 | 海南美大制药有限公司 | 一种头孢替唑钠混悬制剂及其新应用 |
-
2010
- 2010-07-29 CN CN2010102391745A patent/CN101912361B/zh not_active Expired - Fee Related
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101584665A (zh) * | 2009-07-17 | 2009-11-25 | 山东罗欣药业股份有限公司 | 一种盐酸头孢替安药物组合物无菌粉针剂及其制备方法 |
CN101785756A (zh) * | 2010-01-26 | 2010-07-28 | 海南美大制药有限公司 | 一种头孢替唑钠混悬制剂及其新应用 |
Non-Patent Citations (3)
Title |
---|
LG. Alonso et al..Pharmacokinetics of cefotiam after i.v.administration to healthy volmteers.《International Journal of Pharmaceutics》.1984,第19卷(第3期),第345-349页. * |
夏建民.致病菌与抗菌药物的选择.《上海医药》.1996,(第9期),第17-18页. * |
朱衍庆.甲状腺炎 亚急性甲状腺炎的诊治.《医师进修杂志》.1993,(第12期),第2-3页. * |
Also Published As
Publication number | Publication date |
---|---|
CN101912361A (zh) | 2010-12-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101502533B1 (ko) | 우수한 안정성을 갖는 택산 유도체 함유 주사제용동결건조 조성물 및 이의 제조방법 | |
CN101912361B (zh) | 一种盐酸头孢替安/无水碳酸钠药物组合物混悬注射剂及其新应用 | |
CN102755296B (zh) | 一种含有福沙吡坦的无菌冻干制剂及其制备方法 | |
Pilkington et al. | Prevention of gastrointestinal bleeding due to stress ulceration: a review of current literature | |
CN103370066B (zh) | 用于治疗癌症的包含威罗菲尼和干扰素的组合疗法 | |
US20150118322A1 (en) | Biomedical composition | |
CN101559040A (zh) | 一种盐酸头孢替安的药物组合物及其制剂 | |
CN101129368B (zh) | 含有兰索拉唑的冻干粉针 | |
CN101530393B (zh) | 一种克林霉素磷酸酯脂质体冻干制剂 | |
CN102342931A (zh) | 替莫唑胺的可注射的胃肠外用药物制剂及其制备方法 | |
CN107519136A (zh) | 一种氯化琥珀胆碱冻干制剂及其制备方法 | |
CN102210686A (zh) | 一种含更昔洛韦化合物的药物组合物及其制备方法 | |
CN101225093B (zh) | 氨基糖苷类衍生物 | |
CN100502878C (zh) | 夫西地酸钠组合物及其冻干制剂制备方法 | |
CN103315947A (zh) | 一种注射用替加环素组合物 | |
CN101780053B (zh) | 一种头孢美唑钠混悬粉针剂及其新应用 | |
CN112353799A (zh) | 一种注射用西咪替丁组合物及其制备方法与应用 | |
CN105998055A (zh) | 一种含维生素c钠的注射剂及其制备方法 | |
CN101926807A (zh) | 果糖组合药物 | |
CN1526396A (zh) | 一种可注射给药的盐酸头孢甲肟新剂型 | |
CN100516071C (zh) | 头孢类化合物的氨丁三醇盐及其制备方法 | |
CN101129374B (zh) | 长春氟宁药物组合物及其制备方法与应用 | |
CN103585119A (zh) | 一种包含依前列醇及其药用盐的稳定化制剂及其制备方法 | |
CN112451475B (zh) | 一种用于治疗空洞型肺结核的长效缓释凝胶 | |
CN117398337B (zh) | 一种奥拉帕尼缓控释药物组合物及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HAINAN YONGTIAN PHARMACEUTICAL INSTITUTE CO., LTD. Free format text: FORMER OWNER: TAO LINGGANG Effective date: 20130723 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 570125 HAIKOU, HAINAN PROVINCE TO: 570216 HAIKOU, HAINAN PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20130723 Address after: 570216 C03, Haikou Free Trade Zone, Hainan, China Patentee after: Hainan Yongtian Pharmaceutical Institute Co., Ltd. Address before: The new business building No. 48 570125 Hainan city of Haikou province China World Trade Center Road, room 2601 Patentee before: Tao Linggang |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120307 Termination date: 20160729 |
|
CF01 | Termination of patent right due to non-payment of annual fee |